CCR2 and hepatocellular carcinoma: The CCL2-CCR2 axis further contributes to immune suppression, with CCR2 inhibitors like CCX872 showing promise in combination with PD-L1 blockade for HCC (Liang et al., 2023a; Xie et al., 2023).